{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:34:20Z","timestamp":1787315660489,"version":"build-2736575974"},"reference-count":33,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Allogeneic hematopoietic stem cell transplantation (HSCT) is highly effective for treating pediatric high-risk or relapsed acute lymphoblastic leukemia (ALL). For young children, total body irradiation (TBI) is associated with severe late sequelae. In the FORUM study (NCT01949129), we assessed safety, event-free survival (EFS), and overall survival (OS) of 2 TBI-free conditioning regimens in children aged &amp;lt;4 years with ALL. Patients received fludarabine (Flu), thiotepa (Thio), and either busulfan (Bu) or treosulfan (Treo) before HSCT. From 2013 to 2021, 191 children received transplantation and were observed for \u22656\u00a0months (median follow-up: 3 years). The 3-year OS was 0.63 (95% confidence interval [95%\u00a0CI], 0.52-0.72) and 0.76 (95%\u00a0CI, 0.64-0.84) for Flu\/Thio\/Bu and Flu\/Thio\/Treo (P\u00a0= .075), respectively. Three-year EFS was 0.52 (95%\u00a0CI, 0.41-0.61) and 0.51 (95%\u00a0CI, 0.39-0.62), respectively (P\u00a0= .794). Cumulative incidence of nonrelapse mortality (NRM) and relapse at 3 years were 0.06 (95%\u00a0CI, 0.02-0.12) vs 0.03 (95% CI: &amp;lt;0.01-0.09) (P\u00a0= .406) and 0.42 (95%\u00a0CI, 0.31-0.52) vs 0.45 (95%\u00a0CI, 0.34-0.56) (P\u00a0= .920), respectively. Grade &amp;gt;1 acute graft-versus-host disease (GVHD) occurred in 29% of patients receiving Flu\/Thio\/Bu and 17% of those receiving Flu\/Thio\/Treo (P\u00a0= .049), whereas grade 3\/4 occurred in 10% and 9%, respectively (P\u00a0= .813). The 3-year incidence of chronic GVHD was 0.07 (95%\u00a0CI, 0.03-0.13) vs 0.05 (95%\u00a0CI, 0.02-0.11), respectively (P\u00a0= .518). In conclusion, both chemotherapeutic conditioning regimens were well tolerated and NRM was low. However, relapse was the major cause of treatment failure. This trial was registered at www.clinicaltrials.gov as #NCT01949129.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010591","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T11:44:17Z","timestamp":1695383057000},"page":"416-428","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-0265","authenticated-orcid":false,"given":"Peter","family":"Bader","sequence":"first","affiliation":[{"name":"1Goethe University, University Hospital, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"P\u00f6tschger","sequence":"additional","affiliation":[{"name":"2St. Anna Children's Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Hugues","family":"Dalle","sequence":"additional","affiliation":[{"name":"3Pediatric Hematology and Immunology Department, Robert Debr\u00e9 Hospital, Groupe Hospitalo-Universitaire Assistance Publique H\u00f4pitaux de Paris (GHU AP-HP) Nord, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Moser","sequence":"additional","affiliation":[{"name":"1Goethe University, University Hospital, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-0610","authenticated-orcid":false,"given":"Adriana","family":"Balduzzi","sequence":"additional","affiliation":[{"name":"4Universit\u00e0 degli Studi di Milano-Fondazione, FONDAZIONE MONZA E BRIANZA PER IL BAMBINO E LA SUA MAMMA (MBBM), Department for Pediatric Hematology and Oncology, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[{"name":"5CANSEARCH Research Platform for Pediatric Oncology and Hematology, Faculty of Medicine, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Switzerland"},{"name":"6Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Geneva Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-4501","authenticated-orcid":false,"given":"Jochen","family":"Buechner","sequence":"additional","affiliation":[{"name":"7Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-1186","authenticated-orcid":false,"given":"Tayfun","family":"G\u00fcng\u00f6r","sequence":"additional","affiliation":[{"name":"8Department of Hematology\/Oncology\/Immunology, Gene Therapy, and Stem Cell Transplantation, University Children's Hospital Z\u00fcrich, Eleonore Foundation & Children\u2019s Research Center, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Ifversen","sequence":"additional","affiliation":[{"name":"9Copenhagen University Hospital Rigshospitalet, Department for Pediatric Hematology and Oncology, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Krivan","sequence":"additional","affiliation":[{"name":"10Pediatric Hematology and Stem Cell Transplantation Department, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-5123","authenticated-orcid":false,"given":"Herbert","family":"Pichler","sequence":"additional","affiliation":[{"name":"11St. Anna Children's Hospital, University Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Renard","sequence":"additional","affiliation":[{"name":"12Department of Paediatric Oncology, University Hospital Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Staciuk","sequence":"additional","affiliation":[{"name":"13Hospital de Pediatr\u00eda \u201cProf. Dr. Juan P. Garrahan,\u201d Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-2886","authenticated-orcid":false,"given":"Petr","family":"Sedlacek","sequence":"additional","affiliation":[{"name":"14Department of Pediatric Hematology and Oncology, Motol University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Stein","sequence":"additional","affiliation":[{"name":"15Schneider Children's Medical Center of Israel and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5753-0817","authenticated-orcid":false,"given":"Jan Robert","family":"Heusel","sequence":"additional","affiliation":[{"name":"1Goethe University, University Hospital, Department of Pediatrics, Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Truong","sequence":"additional","affiliation":[{"name":"16Division of Pediatric Oncology and Cellular Therapy, Alberta Children's Hospital, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wachowiak","sequence":"additional","affiliation":[{"name":"17Department of Pediatric Oncology, Hematology and Transplantology, Pozna\u0144 University of Medical Sciences, Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif","family":"Yesilipek","sequence":"additional","affiliation":[{"name":"18Medical Park Antalya Hospital, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"19Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Pediatrico Bambino Ges\u00f9, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-8515","authenticated-orcid":false,"given":"Christina","family":"Peters","sequence":"additional","affiliation":[{"name":"2St. Anna Children's Cancer Research Institute, Vienna, Austria"},{"name":"11St. Anna Children's Hospital, University Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"issue":"12","key":"2024011922111518200_bib1","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"2024011922111518200_bib2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pbc.25454","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2","volume":"62","author":"Raetz","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"2024011922111518200_bib3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","article-title":"Outcomes after induction failure in childhood acute lymphoblastic leukemia","volume":"366","author":"Schrappe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024011922111518200_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","article-title":"Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group","volume":"47","author":"von Stackelberg","year":"2011","journal-title":"Eur J Cancer"},{"issue":"19","key":"2024011922111518200_bib5","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/bloodadvances.2020004157","article-title":"Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia","volume":"5","author":"Takachi","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2024011922111518200_bib6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.bbmt.2017.04.017","article-title":"Survival and late effects after allogeneic hematopoietic cell transplantation for hematologic malignancy at less than three years of age","volume":"23","author":"Vrooman","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2024011922111518200_bib7","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024011922111518200_bib8","first-page":"1926","article-title":"Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia","volume":"10","author":"Inaba","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"36","key":"2024011922111518200_bib9","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1200\/JCO.2006.06.2679","article-title":"Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95","volume":"24","author":"Schrauder","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024011922111518200_bib10","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024011922111518200_bib11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3324\/haematol.12291","article-title":"Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time","volume":"93","author":"Balduzzi","year":"2008","journal-title":"Haematologica"},{"issue":"21","key":"2024011922111518200_bib12","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","article-title":"Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group","volume":"31","author":"Eckert","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024011922111518200_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bmt.1705891","article-title":"Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia","volume":"41","author":"Ishaqi","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"9486","key":"2024011922111518200_bib14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(05)66998-X","article-title":"Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study","volume":"366","author":"Balduzzi","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"2024011922111518200_bib15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024011922111518200_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024011922111518200_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FTD.0000000000000468","article-title":"Therapeutic drug monitoring of busulfan for the management of pediatric patients: cross-validation of methods and long-term performance","volume":"40","author":"Choong","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"4","key":"2024011922111518200_bib18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"282","key":"2024011922111518200_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"1","key":"2024011922111518200_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41409-020-01014-x","article-title":"The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG","volume":"56","author":"Dalle","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2024011922111518200_bib21","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/bmt.2016.139","article-title":"Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters","volume":"51","author":"Bresters","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"2024011922111518200_bib22","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 Protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024011922111518200_bib23","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2024011922111518200_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/bmt.2016.224","article-title":"Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience","volume":"52","author":"Willasch","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2024011922111518200_bib25","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","article-title":"Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study","volume":"24","author":"Yaniv","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024011922111518200_bib26","author":"Bader","year":"9-11  2023"},{"issue":"35","key":"2024011922111518200_bib27","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1200\/JCO.2014.56.2223","article-title":"Cognitive outcome after pediatric stem-cell transplantation: impact of age and total-body irradiation","volume":"32","author":"Willard","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024011922111518200_bib28","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/bmt.2013.66","article-title":"In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study","volume":"48","author":"Aristei","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2024011922111518200_bib29","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.3390\/cancers15112999","article-title":"Radiation-induced brain injury: age dependency of neurocognitive dysfunction following radiotherapy","volume":"15","author":"Rube","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"2024011922111518200_bib30","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/s41375-022-01693-z","article-title":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial","volume":"36","author":"Eichinger","year":"2022","journal-title":"Leukemia"},{"key":"2024011922111518200_bib31","doi-asserted-by":"crossref","first-page":"807992","DOI":"10.3389\/fped.2022.807992","article-title":"Acute lymphoblastic leukaemia in the youngest: haematopoietic stem cell transplantation and beyond","volume":"10","author":"Balduzzi","year":"2022","journal-title":"Front Pediatr"},{"issue":"4","key":"2024011922111518200_bib32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.20.03261","article-title":"Continued role for radiation in the conditioning regimen for children with ALL","volume":"39","author":"Pulsipher","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2024011922111518200_bib33","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/416\/2210533\/blooda_adv-2023-010591-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/2\/416\/2210533\/blooda_adv-2023-010591-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T17:11:56Z","timestamp":1705684316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/2\/416\/497975\/Low-rate-of-nonrelapse-mortality-in-under-4-year"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010591","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]}}}